Discovery of new orally active phosphodiesterase (PDE4) inhibitors

Chem Pharm Bull (Tokyo). 2004 Sep;52(9):1098-104. doi: 10.1248/cpb.52.1098.

Abstract

A series of 4-anilinopyrazolopyridine derivatives were synthesized and biologically evaluated as inhibitors of phosphodiesterase (PDE4). Chemical modification of 3, a structurally new chemical lead that was found in our in-house library, was focused on 1- and 3-substituents. Full details of the discovery of a new orally active chemical lead 5 are presented. Structure-activity relationship data, pharmacological evaluation, and the subtype selectivity study are also presented.

MeSH terms

  • 3',5'-Cyclic-AMP Phosphodiesterases / antagonists & inhibitors*
  • Animals
  • Bronchoconstriction / drug effects
  • Cyclic Nucleotide Phosphodiesterases, Type 4
  • Ferrets
  • Gastric Emptying / drug effects
  • Guinea Pigs
  • Humans
  • Lipopolysaccharides / antagonists & inhibitors
  • Male
  • Phosphodiesterase Inhibitors / chemical synthesis
  • Phosphodiesterase Inhibitors / pharmacology
  • Pyrazoles / chemical synthesis*
  • Pyrazoles / pharmacology
  • Pyridines / chemical synthesis*
  • Pyridines / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • SRS-A / pharmacology
  • Structure-Activity Relationship
  • Tumor Necrosis Factor-alpha / biosynthesis
  • Vomiting / chemically induced

Substances

  • Lipopolysaccharides
  • Phosphodiesterase Inhibitors
  • Pyrazoles
  • Pyridines
  • SRS-A
  • Tumor Necrosis Factor-alpha
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 4